Get started
HUTCHMED (China) LimitedHH

HUTCHMED (China) Limited

14.20USDR
−0.42−2.87%
As of today at 17:28 GMT
USD
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals Options

HCM fundamentals

Key facts

Market capitalization‪2.58 B‬USD
Dividend yield (indicated)—
Price to earnings Ratio (TTM)67.65
Basic EPS (TTM)0.22USD
Founded2000
Employees (FY)‪1.81 K‬
CEOWei Guo Su
Websitehutch-med.com
About

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Ownership
‪‪174.32 M‬‬
Free Float shares
‪‪170.32 M‬‬ (97.7%)
Closely held shares
‪‪4.00 M‬‬ (2.3%)
Free Float shares
‪‪170.32 M‬‬ (97.7%)
Closely held shares
‪‪4.00 M‬‬ (2.3%)
Capital structure
Market cap
‪‪2.58 B‬‬
Debt
‪‪89.82 M‬‬
Minority interest
‪‪11.92 M‬‬
Cash & equivalents
‪‪836.11 M‬‬
Enterprise value
‪‪1.84 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪2.58 B‬‬
Price to earning ratio (P/E)
67.65x
Price to sales ratio (P/S)
4.05x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
67.65x
Price to sales ratio (P/S)
4.05x
Valuation ratios
‪0.00‬
‪1.50‬
‪3.00‬
‪4.50‬
‪6.00‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪8.00‬
‪16.00‬
‪24.00‬
‪32.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−105%‬
‪−70%‬
‪−35%‬
‪0%‬
‪35%‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−210.00 M‬‬
‪0.00‬
‪‪210.00 M‬‬
‪‪420.00 M‬‬
‪‪630.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−110.00 M‬‬
‪0.00‬
‪‪110.00 M‬‬
‪‪220.00 M‬‬
‪‪330.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪90.00 M‬‬
‪‪180.00 M‬‬
‪‪270.00 M‬‬
‪‪360.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Oncology/Immunology - Marketed Products
Other Ventures
Oncology/Immunology - Research and Development
By country
Period: 2024
China
United States and Others

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪0.00‬
‪‪150.00 M‬‬
‪‪300.00 M‬‬
‪‪450.00 M‬‬
‪‪600.00 M‬‬
Actual
Estimate
Earnings
Next:Aug 4, 2025
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪−0.60‬
‪0.00‬
‪0.60‬
‪1.20‬
‪1.80‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

HCM does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−320.00 M‬‬
‪‪−160.00 M‬‬
‪0.00‬
‪‪160.00 M‬‬
‪‪320.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪300.00 M‬‬
‪‪600.00 M‬‬
‪‪900.00 M‬‬
‪‪1.20 B‬‬
Assets
Liabilities